Accumetrics platelet response test could guide therapy after CE marking
This article was originally published in Clinica
Executive Summary
Accumetrics has CE marked its VerifyNow P2Y12 test for the identification of poor responders to antiplatelet therapy. Patients who do not respond well to antiplatelet drugs, which inhibit the P2Y12 receptor and therefore blood clotting, are at greater risk for future cardiovascular events.
You may also be interested in...
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.